ScreenerHero

TENX Tenax Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · tenaxthera.com
1.910USD-1.04%Mkt Cap: 71.48M $P/E: —

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II c…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap71.48M USD
Enterprise Value-7.42M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-52.60M USD
Revenue/Share—
Last Price1.910 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.29
PEG1.44
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.88
EPS (TTM)-1.48
EPS (Forward)-1.50
52W Range
1.3103% of range19.40
52W High19.40 USD
52W Low1.310 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-54.19%
ROA-50.47%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-35.80M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-33.64%
Net Debt-117.98M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio15.07
Quick Ratio14.61
Book Value/Sh2.19 USD
Cash/Share2.06 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay DateFeb 26, 2018
Splits
Last Split1:80
Split DateJan 3, 2024
Analyst Consensus
Rating—
Target (Mean)12.56 USD
Upside (mean)+557.4%
Target Range4.000 USD – 36.00 USD
4.000+557.4% to mean36.00
# Analysts9
Ownership
Shares Out.37.42M
Float30.78M
Insiders0.18%
Institutions108.50%
Short Interest
Short Ratio0.8d
Short % Float14.83%
Short % Out.14.71%
Shares Short5.50M
Short (prev mo.)5.47M
Technical
SMA 504.087 (-53.3%)
SMA 20011.09 (-82.8%)
Beta0.92
S&P 52W Chg16.45%
Avg Vol (30d)4.26M
Avg Vol (10d)2.41M
Technical Indicators
RSI (14)28.5
MACD-0.8563
MACD Signal-1.1905
MACD Hist.+0.3342
BB Upper2.057 USD
BB Middle1.913 USD
BB Lower1.770 USD
BB Width14.96%
ATR (14)0.2874 USD
Vol Ratio (20d)0.18x